Amylyx Pharmaceuticals, Inc. (AMLX)
Price:
7.99 USD
( - -0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Incyte Corporation
VALUE SCORE:
9
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
NEWS

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-07 22:35:28Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.

Amylyx (AMLX) Q2 Net Loss Narrows 43%
fool.com
2025-08-07 11:13:46Amylyx (AMLX) Q2 Net Loss Narrows 43%

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
businesswire.com
2025-08-07 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
businesswire.com
2025-07-31 09:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025.

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
seekingalpha.com
2025-07-21 16:26:19Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com
2025-07-14 18:26:00Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
benzinga.com
2025-07-14 14:15:11Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025).

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
businesswire.com
2025-07-13 17:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being.

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
businesswire.com
2025-07-08 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com
2025-07-07 21:00:00NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of long-term stockholders following a class action complaint that was filed against Amylyx on July 1, 2025 with a Class Period from November 11, 2022 to November 8, 2023. Our investigation concerns whether the board of directors of Amylyx have breached their fiduciary duties to the company.

Why Shares in Amylyx Pharmaceuticals Soared This Week
fool.com
2025-06-27 07:56:58Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
benzinga.com
2025-06-24 14:59:09Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia's (PBH) blockbuster potential.

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
2025-06-17 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
accessnewswire.com
2025-06-15 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
accessnewswire.com
2025-06-12 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
globenewswire.com
2025-06-11 10:08:00NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-07 22:35:28Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.

Amylyx (AMLX) Q2 Net Loss Narrows 43%
fool.com
2025-08-07 11:13:46Amylyx (AMLX) Q2 Net Loss Narrows 43%

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
businesswire.com
2025-08-07 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
businesswire.com
2025-07-31 09:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025.

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
seekingalpha.com
2025-07-21 16:26:19Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com
2025-07-14 18:26:00Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
benzinga.com
2025-07-14 14:15:11Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025).

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
businesswire.com
2025-07-13 17:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being.

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
businesswire.com
2025-07-08 07:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
globenewswire.com
2025-07-07 21:00:00NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of long-term stockholders following a class action complaint that was filed against Amylyx on July 1, 2025 with a Class Period from November 11, 2022 to November 8, 2023. Our investigation concerns whether the board of directors of Amylyx have breached their fiduciary duties to the company.

Why Shares in Amylyx Pharmaceuticals Soared This Week
fool.com
2025-06-27 07:56:58Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
benzinga.com
2025-06-24 14:59:09Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia's (PBH) blockbuster potential.

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
2025-06-17 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
accessnewswire.com
2025-06-15 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
accessnewswire.com
2025-06-12 10:00:00NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
globenewswire.com
2025-06-11 10:08:00NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.